Literature DB >> 22274133

CoQ(10) deficiencies and MNGIE: two treatable mitochondrial disorders.

Michio Hirano1, Caterina Garone, Catarina M Quinzii.   

Abstract

BACKGROUND: Although causative mutations have been identified for numerous mitochondrial disorders, few disease-modifying treatments are available. Two examples of treatable mitochondrial disorders are coenzyme Q(10) (CoQ(10) or ubiquinone) deficiency and mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). SCOPE OF REVIEW: Here, we describe clinical and molecular features of CoQ(10) deficiencies and MNGIE and explain how understanding their pathomechanisms have led to rationale therapies. Primary CoQ(10) deficiencies, due to mutations in genes required for ubiquinone biosynthesis, and secondary deficiencies, caused by genetic defects not directly related to CoQ(10) biosynthesis, often improve with CoQ(10) supplementation. In vitro and in vivo studies of CoQ(10) deficiencies have revealed biochemical alterations that may account for phenotypic differences among patients and variable responses to therapy. In contrast to the heterogeneous CoQ(10) deficiencies, MNGIE is a single autosomal recessive disease due to mutations in the TYMP gene encoding thymidine phosphorylase (TP). In MNGIE, loss of TP activity causes toxic accumulations of the nucleosides thymidine and deoxyuridine that are incorporated by the mitochondrial pyrimidine salvage pathway and cause deoxynucleoside triphosphate pool imbalances, which, in turn cause mtDNA instability. Allogeneic hematopoetic stem cell transplantation to restore TP activity and eliminate toxic metabolites is a promising therapy for MNGIE. MAJOR
CONCLUSIONS: CoQ(10) deficiencies and MNGIE demonstrate the feasibility of treating specific mitochondrial disorders through replacement of deficient metabolites or via elimination of excessive toxic molecules. GENERAL SIGNIFICANCE: Studies of CoQ(10) deficiencies and MNGIE illustrate how understanding the pathogenic mechanisms of mitochondrial diseases can lead to meaningful therapies. This article is part of a Special Issue entitled: Biochemistry of Mitochondria, Life and Intervention 2010.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22274133      PMCID: PMC3319470          DOI: 10.1016/j.bbagen.2012.01.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  94 in total

1.  Abdominal pain related to mitochondrial neurogastrointestinal encephalomyopathy syndrome may benefit from splanchnic nerve blockade.

Authors:  Nalan Celebi; Altan Sahin; Ozgür Canbay; Filiz Uzümcügil; Ulkü Aypar
Journal:  Paediatr Anaesth       Date:  2006-10       Impact factor: 2.556

2.  Infusion of platelets transiently reduces nucleoside overload in MNGIE.

Authors:  M C Lara; B Weiss; I Illa; P Madoz; L Massuet; A L Andreu; M L Valentino; Y Anikster; M Hirano; R Martí
Journal:  Neurology       Date:  2006-09-13       Impact factor: 9.910

3.  Missense mutation of the COQ2 gene causes defects of bioenergetics and de novo pyrimidine synthesis.

Authors:  José M López-Martín; Leonardo Salviati; Eva Trevisson; Giovanni Montini; Salvatore DiMauro; Catarina Quinzii; Michio Hirano; Angeles Rodriguez-Hernandez; Mario D Cordero; José A Sánchez-Alcázar; Carlos Santos-Ocaña; Plácido Navas
Journal:  Hum Mol Genet       Date:  2007-03-20       Impact factor: 6.150

4.  Muscle coenzyme Q10 deficiencies in ataxia with oculomotor apraxia 1.

Authors:  I Le Ber; O Dubourg; J-F Benoist; C Jardel; F Mochel; M Koenig; A Brice; A Lombès; A Dürr
Journal:  Neurology       Date:  2007-01-23       Impact factor: 9.910

5.  Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations.

Authors:  Luis Carlos López; Markus Schuelke; Catarina M Quinzii; Tomotake Kanki; Richard J T Rodenburg; Ali Naini; Salvatore Dimauro; Michio Hirano
Journal:  Am J Hum Genet       Date:  2006-10-27       Impact factor: 11.025

6.  Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis.

Authors:  Halûk Yavuz; Ahmet Ozel; Mette Christensen; Ernst Christensen; Marianne Schwartz; Mithat Elmaci; John Vissing
Journal:  Arch Neurol       Date:  2007-03

7.  Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders.

Authors:  Julie Mollet; Irina Giurgea; Dimitri Schlemmer; Gustav Dallner; Dominique Chretien; Agnès Delahodde; Delphine Bacq; Pascale de Lonlay; Arnold Munnich; Agnès Rötig
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

8.  Mitochondrial neurogastrointestinal encephalomyopathy in three siblings: clinical, genetic and neuroradiological features.

Authors:  W M M Schüpbach; K Madhavi Vadday; A Schaller; C Brekenfeld; L Kappeler; J F Benoist; C Nguyen-Thi Xuan-Huong; J M Burgunder; F Seibold; S Gallati; H P Mattle
Journal:  J Neurol       Date:  2007-02-09       Impact factor: 4.849

9.  Mitochondrial DNA depletion and thymidine phosphate pool dynamics in a cellular model of mitochondrial neurogastrointestinal encephalomyopathy.

Authors:  Giovanna Pontarin; Paola Ferraro; Maria L Valentino; Michio Hirano; Peter Reichard; Vera Bianchi
Journal:  J Biol Chem       Date:  2006-06-13       Impact factor: 5.157

10.  Thymidine and deoxyuridine accumulate in tissues of patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).

Authors:  Maria Lucia Valentino; Ramon Martí; Saba Tadesse; Luis Carlos López; Jose L Manes; Judy Lyzak; Angelika Hahn; Valerio Carelli; Michio Hirano
Journal:  FEBS Lett       Date:  2007-06-27       Impact factor: 4.124

View more
  32 in total

Review 1.  Mitochondrial Diseases Part I: mouse models of OXPHOS deficiencies caused by defects in respiratory complex subunits or assembly factors.

Authors:  Alessandra Torraco; Susana Peralta; Luisa Iommarini; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-02-04       Impact factor: 4.160

Review 2.  Mitochondrial biogenesis through activation of nuclear signaling proteins.

Authors:  John E Dominy; Pere Puigserver
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005

Review 3.  The clinical maze of mitochondrial neurology.

Authors:  Salvatore DiMauro; Eric A Schon; Valerio Carelli; Michio Hirano
Journal:  Nat Rev Neurol       Date:  2013-07-09       Impact factor: 42.937

Review 4.  Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies.

Authors:  Susana Peralta; Alessandra Torraco; Luisa Iommarini; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-01-29       Impact factor: 4.160

Review 5.  Drug development for rare mitochondrial disorders.

Authors:  Orest Hurko
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

6.  Treatment with 2,4-Dihydroxybenzoic Acid Prevents FSGS Progression and Renal Fibrosis in Podocyte-Specific Coq6 Knockout Mice.

Authors:  Eugen Widmeier; Merlin Airik; Hannah Hugo; David Schapiro; Johannes Wedel; Chandra C Ghosh; Makiko Nakayama; Ronen Schneider; Agape M Awad; Anish Nag; Jang Cho; Markus Schueler; Catherine F Clarke; Rannar Airik; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2019-02-08       Impact factor: 10.121

Review 7.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 8.  UPR(mt)-mediated cytoprotection and organismal aging.

Authors:  Anna M Schulz; Cole M Haynes
Journal:  Biochim Biophys Acta       Date:  2015-04-07

9.  Mitochondrial function and lifespan of mice with controlled ubiquinone biosynthesis.

Authors:  Ying Wang; Daniella Oxer; Siegfried Hekimi
Journal:  Nat Commun       Date:  2015-03-06       Impact factor: 14.919

Review 10.  [Motility disorders of the esophagus].

Authors:  E Bruder; A-L Rougemont; R I Furlano; J F Schneider; J Mayr; F-M Haecker; K Beier; J Schneider; P Weber; T Berberich; G Cathomas; W A Meier-Ruge
Journal:  Pathologe       Date:  2013-03       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.